(e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide has been researched along with Osteosarcoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ohshima, Y; Suzuki-Karasaki, M; Suzuki-Karasaki, Y; Takata, N; Tokuhashi, Y; Yoshida, Y | 1 |
1 other study(ies) available for (e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide and Osteosarcoma
Article | Year |
---|---|
Mitochondrial Ca2+ removal amplifies TRAIL cytotoxicity toward apoptosis-resistant tumor cells via promotion of multiple cell death modalities.
Topics: Acrylamides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoates; Biological Transport; Bone Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Calcium; Cell Membrane Permeability; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Melanoma; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Osteosarcoma; Oxazoles; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2017 |